Global Alzheimer’s Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer’s Disease
For immediate release: Contact: media@globalalzplatform.org Washington D.C., May 20, The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA’s clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s—a critical […]